Murray J - Search Results

1

US FDA Perspective on Elbasvir/Grazoprevir Treatment for Patients with Chronic Hepatitis C Virus Genotype 1 or 4 Infection.

Boyd SD, Tracy L, Komatsu TE, Harrington PR, Viswanathan P, Murray J, Sherwat A. Boyd SD, et al. Among authors: murray j. Clin Drug Investig. 2017 Apr;37(4):317-326. doi: 10.1007/s40261-017-0492-5. Clin Drug Investig. 2017. PMID: 28102520

2

Ribavirin Reduces Absolute Lymphocyte Counts in Hepatitis C Virus-Infected Patients Treated With Interferon-Free, Direct-Acting Antiviral Regimens.

Harrington PR, Fleischer R, Connelly SM, Lewis LL, Murray J. Harrington PR, et al. Among authors: murray j. Clin Infect Dis. 2015 Sep 15;61(6):974-7. doi: 10.1093/cid/civ419. Epub 2015 May 28. Clin Infect Dis. 2015. PMID: 26021996 Clinical Trial.

3

HCV genotype 4, 5 and 6: Distribution of viral subtypes and sustained virologic response rates in clinical trials of approved direct-acting antiviral regimens.

Boyd SD, Harrington P, Komatsu TE, Naeger LK, Chan-Tack K, Murray J, Birnkrant D, Struble K. Boyd SD, et al. Among authors: murray j. J Viral Hepat. 2018 Aug;25(8):969-975. doi: 10.1111/jvh.12896. Epub 2018 May 8. J Viral Hepat. 2018. PMID: 29577495

4

Reply to Merli et al.

Harrington PR, Fleischer R, Connelly SM, Lewis LL, Murray J. Harrington PR, et al. Among authors: murray j. Clin Infect Dis. 2016 Feb 15;62(4):528-9. doi: 10.1093/cid/civ905. Epub 2015 Oct 27. Clin Infect Dis. 2016. PMID: 26508511 No abstract available.

5

Ibalizumab in Multidrug-Resistant HIV - Accepting Uncertainty.

Sheikh V, Murray JS, Sherwat A. Sheikh V, et al. N Engl J Med. 2018 Aug 16;379(7):605-607. doi: 10.1056/NEJMp1808729. N Engl J Med. 2018. PMID: 30110580 No abstract available.

6

Boceprevir dosing for late responders and null responders: the role of bridging data between treatment-naïve and -experienced subjects.

Florian J, Jadhav PR, Amur S, Ayala R, Harrington P, Mishra P, O'Rear J, Pacanowski M, Robertson S, Singer M, Soon G, Zeng W, Murray J. Florian J, et al. Among authors: murray j. Hepatology. 2013 Mar;57(3):903-7. doi: 10.1002/hep.25843. Epub 2013 Jan 29. Hepatology. 2013. PMID: 22610696 No abstract available.

7

Direct-acting antiviral drug approvals for treatment of chronic hepatitis C virus infection: Scientific and regulatory approaches to clinical trial designs.

Mishra P, Murray J, Birnkrant D. Mishra P, et al. Among authors: murray j. Hepatology. 2015 Oct;62(4):1298-303. doi: 10.1002/hep.27880. Epub 2015 Jun 19. Hepatology. 2015. PMID: 25953139

8

FDA perspective on sofosbuvir therapy for patients with chronic hepatitis C virus genotype 1 infection who did not respond to treatment with pegylated interferon and ribavirin.

Mishra P, Florian J, Qi K, Zeng W, Naeger LK, Donaldson E, Connelly S, O'Rear J, Price D, Murray J, Birnkrant D. Mishra P, et al. Among authors: murray j. Gastroenterology. 2014 Dec;147(6):1196-200. doi: 10.1053/j.gastro.2014.10.027. Epub 2014 Oct 27. Gastroenterology. 2014. PMID: 25449024 No abstract available.

9

Interferon responsiveness does not change in treatment-experienced hepatitis C subjects: implications for drug development and clinical decisions.

Liu J, Florian J, Birnkrant D, Murray J, Jadhav PR. Liu J, et al. Among authors: murray j. Clin Infect Dis. 2012 Sep;55(5):639-44. doi: 10.1093/cid/cis510. Epub 2012 May 31. Clin Infect Dis. 2012. PMID: 22652581

10

Original research: Intravenous ribavirin--review of the FDA's Emergency Investigational New Drug Database (1997-2008) and literature review.

Riner A, Chan-Tack KM, Murray JS. Riner A, et al. Postgrad Med. 2009 May;121(3):139-46. doi: 10.3810/pgm.2009.05.2014. Postgrad Med. 2009. PMID: 19491552 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

7,071 results

Search Page